News – Page 962 – Endpoints News

Bristol-Myers details its failure on Checkmate 451, highlighting a bleak future for their checkpoint combo

7 years ago

Scynexis finds itself in the spotlight with a weapon that may fight a superbug that’s scaring the world to death

7 years ago

Braeburn petitions FDA to revoke Sublocade orphan designation

7 years ago

Regeneron, Alnylam spell out a research alliance that could run beyond a decade, with billions built in for success

7 years ago

Jude Samulski's gene therapy company just raised $235M for clinical development

7 years ago

Faced by R&D setbacks and questionable gains, Gilead’s new CEO’s first move is to reach for the ax

7 years ago

In combat mode, Indivior hunkers down for a war with DoJ over multibillion-dollar fraud charges

7 years ago

FDA, Brigham and Women’s to test if RWE is ripe now for replacing clinical drug trials

7 years ago

Lynparza secures third EU nod; Protein degradation biotech grabs $16M launch round from Chinese VCs; Wave shares ...

7 years ago

Inozyme brings $67M to the bank to build up its calcification-focused rare disease pipeline

7 years ago

Chinese player joins a growing group of biotechs buying into Synaffix's ADC linker tech

7 years ago

Compared to avoidance, Aimmune's peanut allergy treatment an improvement over DBV's product — ICER

7 years ago

Gene therapies for the cats and dogs you love? Penn-partnered Scout Bio just raised $20M to make it a reality

7 years ago

As public furor mounts, Sanofi makes deep cuts to US insulin prices in savings program

7 years ago

Once spurned, Amgen wins the FDA over with its bone-building osteoporosis drug Evenity

7 years ago

Two more Big Pharma CEOs enjoyed hefty raises in 2018, leaving the industry’s only major league female chief in ...

7 years ago

WuXi AppTec recruits new CMO; Embattled Alkermes makes case for expanded use of schizophrenia drug Aristada

7 years ago

Two Republican lawmakers feel 'obliged' to warn drugmakers that Democrat colleague Cummings is purportedly out to ...

7 years ago

Peter Hecht recruits Bayer/Shire vet Andreas Busch for a top R&D post at his $175M biotech spinout

7 years ago

BeiGene lines up a next-gen CTLA-4 to complement its PD-1 pillar in new deal worth up to $270M

7 years ago

Poxel, partner Sumitomo Dainippon taste success in first pivotal test for oral diabetes drug

7 years ago

After revamping R&D in a global shakeup, Bayer prepping new labs for an expansion in cancer research at MIT

7 years ago

PhaseBio touts 'breakthrough' badge for bloodthinner reversal agent licensed from AstraZeneca, shares leap

7 years ago

It’s a seller’s world in biotech M&A, and Novartis CEO Vas Narasimhan has his check book out and pen ready

7 years ago

First page Previous page 959 960 961962963 964 965 Next page Last page